Tom 2, Nr 3-4 (2024)
Artykuł przeglądowy
Opublikowany online: 2025-02-02
Roztwory do stosowania miejscowego w leczeniu łysienia androgenowego — ocena skuteczności i bezpieczeństwa
1
, 2
, 2
Dermatologia w Praktyce Klinicznej 2024;2(3-4):85-93.
Streszczenie
Łysienie androgenowe (AGA, androgenic alopecia) ze względu na swoje rozpowszechnienie i wpływ na jakość życia pacjentów stanowi poważne wyzwanie w praktyce klinicznej. Przy szerokim spektrum dostępnych metod leczenia wybór najbardziej odpowiedniej terapii wymaga starannego rozważenia czynników takich jak skuteczność, bezpieczeństwo, praktyczność i koszt. Celem niniejszego przeglądu jest dokonanie oceny skuteczności i profili bezpieczeństwa różnych metod miejscowego leczenia AGA oraz zbadanie ich potencjalnych zalet w ograniczaniu ogólnoustrojowych działań niepożądanych w porównaniu z lekami doustnymi. W artykule omówiono farmakologię, mechanizmy działania, skuteczność kliniczną i zdarzenia niepożądane związane ze stosowanymi miejscowo lekami, takimi jak minoksydyl, finasteryd, szampony z ketokonazolem, klaskoteron, latanoprost, spironolakton, flutamid, cetyryzyna, pirylutamid i GT20029.
Słowa kluczowe: łysienie androgenoweleczeniemiejscoweminoksydylfinasterydklaskoteron
Referencje
- Hamilton JB. Male hormone stimulation is prerequisite and an incitant in common baldness. Am J Anat. 2005; 71(3): 451–480.
- Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977; 97(3): 247–254.
- Kabir Y, Goh C. Androgenetic alopecia. J Egypt Women’s Dermatologic Soc. 2013; 10(3): 107–116.
- Suchonwanit P, Srisuwanwattana P, Chalermroj N, et al. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol. 2018; 32(12): 2257–2263.
- Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: a randomized, double-blind, controlled study. Am J Clin Dermatol. 2019; 20(1): 147–153.
- Ando Y, Yamaguchi Y, Hamada K, et al. Expression of mRNA for androgen receptor, 5alpha-reductase and 17beta-hydroxysteroid dehydrogenase in human dermal papilla cells. Br J Dermatol. 1999; 141(5): 840–845.
- Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry. 2012; 73(9): 1220–1223.
- Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011; 8(6): 1747–1753.
- Ramos PM, Sinclair RD, Kasprzak M, et al. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial. J Am Acad Dermatol. 2020; 82(1): 252–253.
- Randolph M, Tosti A. Oral minoxidil treatment for hair loss: a review of efficacy and safety. J Am Acad Dermatol. 2021; 84(3): 737–746.
- Li M, Marubayashi A, Nakaya Y, et al. Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol. 2001; 117(6): 1594–1600.
- Galbraith GM, Thiers BH. In vitro suppression of human lymphocyte activity by minoxidil. Int J Dermatol. 1985; 24(4): 249–251.
- Pekmezci E, Turkoğlu M, Gökalp H, et al. Minoxidil downregulates interleukin-1 alpha gene expression in HaCaT cells. Int J Trichology. 2018; 10(3): 108–112.
- Kvedar JC, Baden HP, Levine L. Selective inhibition by minoxidil of prostacyclin production by cells in culture. Biochem Pharmacol. 1988; 37(5): 867–874.
- Navarro MR, Asín M, Martínez MA, et al. Management of androgenetic alopecia: a comparative clinical study between plasma rich in growth factors and topical minoxidil. Eur J Plast Surg. 2016; 39(3): 173–180.
- Rundegren J. A one-year observational study with minoxidil 5% solution in Germany: results of independent efficacy evaluation by physicians and patients. J Am Acad Dermatol. 2004; 50(3): P91.
- Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002; 47(3): 377–385.
- McCoy J, Goren A, Kovacevic M, et al. Minoxidil dose response study in female pattern hair loss patients determined to be non-responders to 5% topical minoxidil. J Biol Regul Homeost Agents. 2016; 30(4): 1153–1155.
- Traish AM. Post-finasteride syndrome: a surmountable challenge for clinicians. Fertil Steril. 2020; 113(1): 21–50.
- Coskuner ER, Ozkan B, Culha MG. Sexual problems of men with androgenic alopecia treated with 5-alpha reductase inhibitors. Sex Med Rev. 2019; 7(2): 277–282.
- Liu L, Zhao S, Li F, et al. Effect of 5α-reductase inhibitors on sexual function: a meta-analysis and systematic review of randomized controlled trials. J Sex Med. 2016; 13(9): 1297–1310.
- Mazzarella GF, Loconsole GF, Cammisa GA, et al. Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course. J Dermatolog Treat. 2009; 8(3): 189–192.
- Piraccini BM, Blume-Peytavi U, Scarci F, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022; 36(2): 286–294.
- Suchonwanit P, Srisuwanwattana P, Chalermroj N, et al. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol. 2018; 32(12): 2257–2263.
- Caserini M, Radicioni M, Leuratti C, et al. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. Int J Clin Pharmacol Ther. 2016; 54(1): 19–27.
- Fields JR, Vonu PM, Monir RL, et al. Topical ketoconazole for the treatment of androgenetic alopecia: a systematic review. Dermatol Ther. 2020; 33(1): e13202.
- Whiting DA, Waldstreicher J, Sanchez M, et al. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women. J Investig Dermatol Symp Proc. 1999; 4(3): 282–284.
- Piérard-Franchimont C, Goffin V, Henry F, et al. Nudging hair shedding by antidandruff shampoos. A comparison of 1% ketoconazole, 1% piroctone olamine and 1% zinc pyrithione formulations. Int J Cosmet Sci. 2002; 24(5): 249–256.
- Piérard-Franchimont C, De Doncker P, Cauwenbergh G, et al. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology. 1998; 196(4): 474–477.
- Rafi AW, Katz RM. Pilot study of 15 patients receiving a new treatment regimen for androgenic alopecia: the effects of atopy on AGA. ISRN Dermatol. 2011; 2011: 241953.
- Rosette C, Rosette N, Mazzetti A, et al. Cortexolone 17α-propionate (clascoterone) is an androgen receptor antagonist in dermal papilla cells in vitro. J Drugs Dermatol. 2019; 18(2): 197–201.
- A summary of in vitro, phase I, and phase II studies evaluating the mechanism of action, safety, and efficacy of clascoterone (cortexolone 17a propionate, CB-03-01) in androgenetic alopecia. J Am Acad Dermatol. 2019; 81(4): AB13.
- Dhillon S. Clascoterone: first approval. Drugs. 2020; 80(16): 1745–1750.
- Mazzetti A, Moro L, Gerloni M, et al. A phase 2b, randomized, double-blind vehicle controlled, dose escalation study evaluating clascoterone 0.1%, 0.5%, and 1% topical cream in subjects with facial acne. J Drugs Dermatol. 2019; 18(6): 570.
- Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997; 124(4): 544–547.
- Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol. 2002; 47 Suppl 1: S185–S202.
- Blume-Peytavi U, Lönnfors S, Hillmann K, et al. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol. 2012; 66(5): 794–800.
- Ioannides D, Lazaridou E. Female pattern hair loss. Curr Probl Dermatol. 2015; 47: 45–54.
- Abdel-Raouf H, Aly UF, Medhat W, et al. A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: clinical, histopathological, and physicochemical study. Dermatol Ther. 2021; 34(1): e14678.
- Ammar AM, Elshahid AR, Abdel-Dayem HA, et al. Dermoscopic evaluation of the efficacy of combination of topical spironolactone 5% and minoxidil 5% solutions in the treatment of androgenetic alopecia: A cross sectional-comparative study. J Cosmet Dermatol. 2022; 21(11): 5790–5799.
- Sintov A, Serafimovich S, Gilhar A. New topical antiandrogenic formulations can stimulate hair growth in human bald scalp grafted onto mice. Int J Pharm. 2000; 194(1): 125–134.
- Faghihi G, Iraji F, Siadat AH, et al. Comparison between “5% minoxidil plus 2% flutamide” solution vs. “5% minoxidil” solution in the treatment of androgenetic alopecia. J Cosmet Dermatol. 2022; 21(10): 4447–4453.
- Bassiouny EA, El-Samanoudy SI, Abbassi MM, et al. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Arch Dermatol Res. 2023; 315(5): 1293–1304.
- Hossein Mostafa D, Samadi A, Niknam S, et al. Efficacy of cetirizine 1% versus minoxidil 5% topical solution in the treatment of male alopecia: a randomized, single-blind controlled study. J Pharm Pharm Sci. 2021; 24: 191–199.
- Alavi SM, Layegh P, Vahabi-Amlashi S, et al. Therapeutic effects of topical cetirizine in the treatment of female pattern hair loss: a randomized controlled noninferiority trial. Expert Rev Clin Pharmacol. 2023; 16(10): 1009–1015.
- The safety, tolerability and PK of KX-826 in healthy males with alopecia following topical multiple dose ascending. https://clinicaltrials. gov/study/NCT04502901 (9.06.2024).
- Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult AGA In China Received Clearance By NMPA. https://en.kintor.com. cn/news/254.html (9.06.2024).
- Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US. https:// en.kintor.com.cn/news/245.html (9.06.2024).
- Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AG. https:// en.kintor.com.cn/news/246.html (9.06.2024).
- Kintor Pharma Announced Completion of Phase I Trial of the World’s First PROTAC Compound (GT20029) for Topical Use. https://en.kintor. com.cn/news/233.html (9.06.2024).
- Kintor Pharma’s GT20029 Phase II trial meets primary endpoint. https://www.clinicaltrialsarena.com/news/kintor-trial-aga-treatment/ (11.06.2024).